Waters (WAT) Rises After Q1 Beat as Integration Progress Offsets Sales Decline

Waters Corp. (WAT) shares rose about 15% after the company reported first-quarter results that topped Wall Street revenue and earnings expectations, despite a year-over-year decline in headline sales. Management cited stronger organic growth in legacy divisions and better-than-expected early performance from recently acquired Biosciences and Diagnostic Solutions businesses. CEO Udit Batra said execution of a 180-day integration plan, operational improvements, instrument replacement demand and new product launches supported the quarter. Waters traded at $348.01 after the earnings update, up from $301.88 before the report. Investors are focused on integration progress, synergy capture from the BD-related acquisition, uptake of new diagnostics and analytical sciences products, China manufacturing localization and margin trends tied to cost actions and procurement efficiencies.